Tsukasa Ueda

Kanazawa, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report.

Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 31, 2026

A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report.

A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report.

Journal: Cureus
Published: April 17, 2026

Late Recurrence of Breast Cancer Nearly 30 Years After Surgery: Mediastinal and Hilar Lymph Node Metastases Diagnosed Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration.

Late Recurrence of Breast Cancer Nearly 30 Years After Surgery: Mediastinal and Hilar Lymph Node Metastases Diagnosed Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration.

Journal: Cureus
Published: November 19, 2025

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Journal: Oncogene
Published: October 29, 2025

Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers.

Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers.

Journal: Cancer science
Published: September 12, 2025

MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular Toxicity.

MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular Toxicity.

Journal: Cancer science
Published: July 31, 2025

Prognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancer.

Prognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 10, 2025

Mechanisms of resistance to antibody-drug conjugates in cancers.

Mechanisms of resistance to antibody-drug conjugates in cancers.

Journal: Respiratory investigation
Published: March 31, 2025

Characteristic miRNA profiles represent clinicopathological diversity of small cell lung cancer.

Characteristic miRNA profiles represent clinicopathological diversity of small cell lung cancer.

Journal: The Journal of pathology
Published: February 20, 2025

Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study.

Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 28, 2025

A 72-Year-Old Man With Progressive Dyspnea and Diffuse Lung Disease.

A 72-Year-Old Man With Progressive Dyspnea and Diffuse Lung Disease.

Journal: Chest
Published: January 16, 2025

Severe coronavirus disease 2019 (COVID-19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series.

Severe coronavirus disease 2019 (COVID-19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series.

Journal: Clinical case reports
Published: July 23, 2020
Showing 1-12 of 16

Last Updated: 09/26/2026